Clinical Trial

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-17.
Trial Details
NCT Number NCT07720193
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Collaborators: Peking University Cancer Hospital & Institute
Conditions Advanced Extrapulmonary Neuroendocrine Carcinoma
Enrollment 280 participants
Start Date 2026-08-22
Primary Completion 2030-12-22 (estimated)
Study Completion 2030-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-24